

Special Issue

Pathogenesis, Prophylaxis and Treatment of Infectious Diseases

Message from the Guest Editors

“Pathogenesis, Prophylaxis, Treatment of Infectious Diseases” is a Special Issue that aims to draw the attention of the medical community toward infectious diseases. Global efforts have focused on prevention, and in some cases with success: on the 29th of March 2023, the World Health Organization announced that a total of 42 countries or territories had reached the malaria-free milestone. Yet, there is still much to be done regarding cholera epidemics, monkeypox outbreaks, tuberculosis prevalence, the emergence of the new multidrug-resistant fungus *Candida auris* and many more. We aim to attract as much new information as possible about infectious disease agents and their pathogenesis and treatment, and prevention and prophylaxis are highly required. In this Special Issue, we welcome original articles and reviews providing new research data on infectious diseases, irrespective of the etiology, whether that be bacterial, viral, parasitic or mycotic, and on novel biomarkers, early diagnosis, pathology, molecular mechanisms, new therapies and prophylactic means.

Guest Editors

Dr. Loredana Manolescu

Faculty of Midwifery and Nursing, “Carol Davila” University of Medicine and Pharmacy, Eroii Sanitari Boulevard, no. 8, Sector 5, 050474 Bucharest, Romania

Dr. Anca Botezatu

Molecular Virology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/177377

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).